SBI-477 is a novel and potent small molecule chemical probe stimulated insulin signaling by deactivating the transcription factor MondoA, leading to reduced expression of the insulin pathway suppressors thioredoxin-interacting protein (TXNIP) and arrestin domain–containing 4 (ARRDC4). SBI-477 coordinately inhibits triacylglyceride (TAG) synthesis and enhances basal glucose uptake in human skeletal myocytes. It has the potential to be used as a therapeutic agebt for insulin resistance and lipotoxicity.

纯度：≥98%

CAS：781628-99-7